Michelle Nelson

Director, Immunobiology at Aptevo Therapeutics Inc.

Presenter

Michelle H. Nelson, PhD, Senior Director at Aptevo Therapeutics, has two decades of experience in viral and cancer immunology, T cell engineering and translational oncology. She currently leads the immunology team in the discovery and preclinical development of innovative tumor-targeted antibody-like biologics using Aptevo's proprietary platform technology, ADAPTIR(tm) and ADAPTIR-FLEX(tm), successfully progressing assets from early-stage discovery through FDA-cleared IND applications in both hematologic and solid tumor indications. Beyond the lab, Dr. Nelson bridges the gap between science and strategy, representing Aptevo as the principal scientific presenter in business development and investor relations meetings.